MDMA
Massachusetts Bill Would Cap MDMA Therapy Costs at $5,000
The article Massachusetts Bill Would Cap MDMA Therapy Costs at $5,000 was originally published on Microdose.
…Any person or entity registered to prescribe,…
The article Massachusetts Bill Would Cap MDMA Therapy Costs at $5,000 was originally published on Microdose.
…Any person or entity registered to prescribe, manufacture, distribute, dispense or provide services related to 3,4-methylenedioxymethamphetamine (MDMA) shall not charge more than $5,000 per MDMA treatment service unit.
This is the language used in bill HD2137, filed by Massachusetts State Representative. Nick Boldyga, a Republican, has proposed a bill that would not only re-schedule MDAM automatically upon FDA approval but cap the cost of treatment to $5,000.
The bill is at its earliest stage and has a ways to go, but it’s a sign that legislators (a Republicans at that) are taking the future of psychedelic medicine and access seriously.
As for cost concerns, according to several estimates and this piece in the Washington Post, the initial roll-out of MAPS’ MDMA therapy could reach $15,000.
If and when the FDA approves MDMA used for PTSD, it will not be widely available; it will be an option only for people with a formal clinical diagnosis of PTSD. It will also be incredibly expensive: Estimates range from $13,000 to $15,000 per treatment round, and it’s not clear what might be covered by health insurance.
With PTSD affecting people across all demographics, and with groups like veterans suffering disproportionately and not always having access to resources – questions of costs will be important. Will the VA (Veterans Association) cover MDMA therapy? Will regular insurance?
While legal price-capping might not be the solution, especially for a non-profit like MAPS, the conversation is an important one to have.
mdma psychedelic therapy ptsd fda
-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin4 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics3 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics4 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID